Posted by Michael Wonder on 04 Jun 2020
NICE publishes final guidance backing Teva's Ajovy for migraine
4 June 2020 - NICE has now published final guidelines endorsing the NHS use of Teva’s Ajovy (fremanezumab) to prevent migraine.
The decision means use of the drug will be funded by the NHS in adults with chronic migraine who have not responded to at least three prior preventive treatments.
In this subset of patients, clinical trial evidence shows that Ajovy works better than best supportive care in both episodic and chronic migraine. However, it is unclear if fremanezumab works better than botulinum toxin type A, NICE said.
